Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18-70
SponsorWomen's Hospital School Of Medicine Zhejiang University
About this trial
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery;
Positive PD-L1 expression;
ECOG score ≤1
Disqualifiers
Positive parametrium or surgical margin;
Incomplete radical surgery;
Residual target lesions;
Active autoimmune disease or autoimmune disease requiring systemic treatment;
Trial design
Design model
Single group
Treatments tested in this trial
Camrelizumab combined with chemotherapy
DrugCamrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery
Treatment groups
59 Participants
are divided into 1 treatment groupGroup A: chemotherapy groupExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
3-year disease-free survival rate
Time frame
from enrollment until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 100 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov